Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV), BioLife Solutions (BLFS) and Avita Medical (RCEL)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Acrivon Therapeutics, Inc. (ACRV – Research Report), BioLife Solutions (BLFS – Research Report) and Avita Medical (RCEL – Research Report) with bullish sentiments.

Acrivon Therapeutics, Inc. (ACRV)

In a report released yesterday, Matthew Biegler from Oppenheimer reiterated a Buy rating on Acrivon Therapeutics, Inc., with a price target of $25.00. The company’s shares closed last Thursday at $4.59.

According to TipRanks.com, Biegler has 0 stars on 0-5 stars ranking scale with an average return of -14.3% and a 25.0% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Zentalis Pharmaceuticals, and Olema Pharmaceuticals.

Acrivon Therapeutics, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $24.33, implying a 345.6% upside from current levels. In a report released yesterday, JonesTrading also maintained a Buy rating on the stock with a $26.00 price target.

See today’s best-performing stocks on TipRanks >>

BioLife Solutions (BLFS)

In a report released yesterday, Steven Mah from TD Cowen maintained a Buy rating on BioLife Solutions, with a price target of $20.00. The company’s shares closed last Thursday at $11.39, close to its 52-week low of $8.92.

According to TipRanks.com, Mah has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -18.5% and a 21.1% success rate. Mah covers the Healthcare sector, focusing on stocks such as Ginkgo Bioworks Holdings, Rapid Micro Biosystems, and AbCellera Biologics.

BioLife Solutions has an analyst consensus of Strong Buy, with a price target consensus of $22.50.

Avita Medical (RCEL)

In a report released yesterday, Ryan Zimmerman from BTIG maintained a Buy rating on Avita Medical, with a price target of $20.00. The company’s shares closed last Thursday at $9.88.

According to TipRanks.com, Zimmerman is a 4-star analyst with an average return of 3.5% and a 40.0% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Treace Medical Concepts, and Zimmer Biomet Holdings.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Avita Medical with a $27.25 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ACRV:

• Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
• Acrivon Therapeutics presents data on AP platform, ACR-368 OncoSignature Assay
• Acrivon Therapeutics management to meet with Oppenheimer
• Acrivon Therapeutics Inc trading resumes
• Acrivon Therapeutics Inc trading halted, volatility trading pause